{
    "markdown": "<a id='d4ad3519-b0aa-4c1a-b05e-3e3b501c4f9f'></a>\n\n****************************************************************\nPrivileged and Confidential:\nAttorney - Client Communication and\nAttorney Work Product\n****************************************************************\n\n<a id='0e034c61-7e60-490d-a6f8-2aaffaf2b882'></a>\n\n3. Documents relating to preclinical studies, clinical trials, epidemiological studies or other studies involving ACTOS\u00ae or ACTOS\u00ae combination medicines, and PPAR Agonists;\n4. Scientific and Medical Affairs documents relating to ACTOS\u00ae or ACTOS\u00ae combination medicines and PPAR Agonists;\n5. Pharmacovigilance (safety surveillance) documents relating to ACTOS\u00ae or ACTOS\u00ae combination medicines, and PPAR Agonists;\n6. Regulatory documents relating to ACTOS\u00ae or ACTOS\u00ae combination medicines, and PPAR Agonists;\n7. Documents relating to the labeling of ACTOS\u00ae or ACTOS\u00ae combination medicines, and PPAR Agonists;\n8. Documents relating to communications, contacts, or interactions with Patients, Physicians, Hospitals, Clinics, other Healthcare Professionals, Third Party Payors, or government entities in the United States regarding ACTOS\u00ae or ACTOS\u00ae combination medicines, and PPAR Agonists (if any);\n9. Documents relating to samples of ACTOS\u00ae or ACTOS\u00ae combination medicines, and PPAR Agonists (if any), provided to Physicians or other Healthcare Professionals in the United States;\n10. Documents relating to marketing and promotion of ACTOS\u00ae or ACTOS\u00ae combination medicines and, and PPAR Agonists (if any) in the United States, including marketing/promotional materials, direct-to-consumer advertising, sales aids, visuals, sales scripts, sales guides, reminder pieces, sales training materials, IMS data, marketing plans, market analysis, and agreements with any person or firm hired to assist with marketing); and,\n11. Documents relating to advisory boards and key opinion leaders in the United States regarding ACTOS\u00ae or ACTOS\u00ae combination medicines, and PPAR Agonists (if any).\n\n<a id='adc01297-4e90-47e6-9ad1-07aec12efa1c'></a>\n\nFor purposes of identifying documents to be preserved, the terms \"relating to\" or \"regarding\" should be understood as broadly as possible and any doubts concerning particular documents should be resolved in favor of preservation. Appropriate preservation of documents in accordance with this Notice is of the highest priority for you and the Company.\n\n<a id='8791c92e-adff-4a7f-90f2-60d81527c4f7'></a>\n\nFor purposes of this Notice, the term \"documents\" should be understood to have the broadest possible meaning. It includes, but is not limited to, paper and electronically stored information:\n\n*   paper documents, includes without limitation, correspondence; faxes; memoranda; notes; desk files, working files, or other personal files; presentations; calendars; contracts or other agreements; financial statements and related materials; message slips; phone logs; reports; statements; manuals; advertisements and other marketing materials; and,\n*   electronically stored information, includes without limitation e-mails and attachments; electronic calendars, task lists, journals, and notes; user files such as Microsoft Word, Excel, or PowerPoint files or Adobe PDF files; video recordings; instant messages;\n\n<a id='94874466-db80-4a15-a892-176dbe51c841'></a>\n\n3\n\n<a id='db6f438b-07b8-4b86-8d25-269d01fea5ca'></a>\n\nConfidential - Subject to Protective Order\n\n<a id='172e8067-cc85-45c7-bb7c-994798fdf00c'></a>\n\nTAK-RIM30b6-00000827\n\n<a id='fbbf39f1-8d62-4fbc-b5ea-a02107e3b037'></a>\n\nSource: https://www.indupP5345-00015ts.ucsf.edu/docs/srjf0226",
    "chunks": [
        {
            "markdown": "<a id='d4ad3519-b0aa-4c1a-b05e-3e3b501c4f9f'></a>\n\n****************************************************************\nPrivileged and Confidential:\nAttorney - Client Communication and\nAttorney Work Product\n****************************************************************",
            "type": "text",
            "id": "d4ad3519-b0aa-4c1a-b05e-3e3b501c4f9f",
            "grounding": {
                "box": {
                    "left": 0.5904516577720642,
                    "top": 0.06997115910053253,
                    "right": 0.8831928372383118,
                    "bottom": 0.1347237527370453
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='0e034c61-7e60-490d-a6f8-2aaffaf2b882'></a>\n\n3. Documents relating to preclinical studies, clinical trials, epidemiological studies or other studies involving ACTOS\u00ae or ACTOS\u00ae combination medicines, and PPAR Agonists;\n4. Scientific and Medical Affairs documents relating to ACTOS\u00ae or ACTOS\u00ae combination medicines and PPAR Agonists;\n5. Pharmacovigilance (safety surveillance) documents relating to ACTOS\u00ae or ACTOS\u00ae combination medicines, and PPAR Agonists;\n6. Regulatory documents relating to ACTOS\u00ae or ACTOS\u00ae combination medicines, and PPAR Agonists;\n7. Documents relating to the labeling of ACTOS\u00ae or ACTOS\u00ae combination medicines, and PPAR Agonists;\n8. Documents relating to communications, contacts, or interactions with Patients, Physicians, Hospitals, Clinics, other Healthcare Professionals, Third Party Payors, or government entities in the United States regarding ACTOS\u00ae or ACTOS\u00ae combination medicines, and PPAR Agonists (if any);\n9. Documents relating to samples of ACTOS\u00ae or ACTOS\u00ae combination medicines, and PPAR Agonists (if any), provided to Physicians or other Healthcare Professionals in the United States;\n10. Documents relating to marketing and promotion of ACTOS\u00ae or ACTOS\u00ae combination medicines and, and PPAR Agonists (if any) in the United States, including marketing/promotional materials, direct-to-consumer advertising, sales aids, visuals, sales scripts, sales guides, reminder pieces, sales training materials, IMS data, marketing plans, market analysis, and agreements with any person or firm hired to assist with marketing); and,\n11. Documents relating to advisory boards and key opinion leaders in the United States regarding ACTOS\u00ae or ACTOS\u00ae combination medicines, and PPAR Agonists (if any).",
            "type": "text",
            "id": "0e034c61-7e60-490d-a6f8-2aaffaf2b882",
            "grounding": {
                "box": {
                    "left": 0.21835893392562866,
                    "top": 0.14801667630672455,
                    "right": 0.8813126683235168,
                    "bottom": 0.5939598083496094
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='adc01297-4e90-47e6-9ad1-07aec12efa1c'></a>\n\nFor purposes of identifying documents to be preserved, the terms \"relating to\" or \"regarding\" should be understood as broadly as possible and any doubts concerning particular documents should be resolved in favor of preservation. Appropriate preservation of documents in accordance with this Notice is of the highest priority for you and the Company.",
            "type": "text",
            "id": "adc01297-4e90-47e6-9ad1-07aec12efa1c",
            "grounding": {
                "box": {
                    "left": 0.1362217664718628,
                    "top": 0.6015820503234863,
                    "right": 0.8594271540641785,
                    "bottom": 0.6735875606536865
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='8791c92e-adff-4a7f-90f2-60d81527c4f7'></a>\n\nFor purposes of this Notice, the term \"documents\" should be understood to have the broadest possible meaning. It includes, but is not limited to, paper and electronically stored information:\n\n*   paper documents, includes without limitation, correspondence; faxes; memoranda; notes; desk files, working files, or other personal files; presentations; calendars; contracts or other agreements; financial statements and related materials; message slips; phone logs; reports; statements; manuals; advertisements and other marketing materials; and,\n*   electronically stored information, includes without limitation e-mails and attachments; electronic calendars, task lists, journals, and notes; user files such as Microsoft Word, Excel, or PowerPoint files or Adobe PDF files; video recordings; instant messages;",
            "type": "text",
            "id": "8791c92e-adff-4a7f-90f2-60d81527c4f7",
            "grounding": {
                "box": {
                    "left": 0.1366363763809204,
                    "top": 0.6831427812576294,
                    "right": 0.8793812990188599,
                    "bottom": 0.8867956399917603
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='94874466-db80-4a15-a892-176dbe51c841'></a>\n\n3",
            "type": "marginalia",
            "id": "94874466-db80-4a15-a892-176dbe51c841",
            "grounding": {
                "box": {
                    "left": 0.5064734816551208,
                    "top": 0.900419294834137,
                    "right": 0.5263796448707581,
                    "bottom": 0.9172058701515198
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='db6f438b-07b8-4b86-8d25-269d01fea5ca'></a>\n\nConfidential - Subject to Protective Order",
            "type": "marginalia",
            "id": "db6f438b-07b8-4b86-8d25-269d01fea5ca",
            "grounding": {
                "box": {
                    "left": 0.05828157067298889,
                    "top": 0.9531840682029724,
                    "right": 0.4446862041950226,
                    "bottom": 0.9734686017036438
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='172e8067-cc85-45c7-bb7c-994798fdf00c'></a>\n\nTAK-RIM30b6-00000827",
            "type": "marginalia",
            "id": "172e8067-cc85-45c7-bb7c-994798fdf00c",
            "grounding": {
                "box": {
                    "left": 0.7563959956169128,
                    "top": 0.9526851177215576,
                    "right": 0.9735433459281921,
                    "bottom": 0.9736084938049316
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='fbbf39f1-8d62-4fbc-b5ea-a02107e3b037'></a>\n\nSource: https://www.indupP5345-00015ts.ucsf.edu/docs/srjf0226",
            "type": "marginalia",
            "id": "fbbf39f1-8d62-4fbc-b5ea-a02107e3b037",
            "grounding": {
                "box": {
                    "left": 0.22159555554389954,
                    "top": 0.9798094630241394,
                    "right": 0.7799657583236694,
                    "bottom": 0.9995104670524597
                },
                "page": 0
            }
        }
    ],
    "splits": [
        {
            "class": "full",
            "identifier": "full",
            "pages": [
                0
            ],
            "markdown": "<a id='d4ad3519-b0aa-4c1a-b05e-3e3b501c4f9f'></a>\n\n****************************************************************\nPrivileged and Confidential:\nAttorney - Client Communication and\nAttorney Work Product\n****************************************************************\n\n<a id='0e034c61-7e60-490d-a6f8-2aaffaf2b882'></a>\n\n3. Documents relating to preclinical studies, clinical trials, epidemiological studies or other studies involving ACTOS\u00ae or ACTOS\u00ae combination medicines, and PPAR Agonists;\n4. Scientific and Medical Affairs documents relating to ACTOS\u00ae or ACTOS\u00ae combination medicines and PPAR Agonists;\n5. Pharmacovigilance (safety surveillance) documents relating to ACTOS\u00ae or ACTOS\u00ae combination medicines, and PPAR Agonists;\n6. Regulatory documents relating to ACTOS\u00ae or ACTOS\u00ae combination medicines, and PPAR Agonists;\n7. Documents relating to the labeling of ACTOS\u00ae or ACTOS\u00ae combination medicines, and PPAR Agonists;\n8. Documents relating to communications, contacts, or interactions with Patients, Physicians, Hospitals, Clinics, other Healthcare Professionals, Third Party Payors, or government entities in the United States regarding ACTOS\u00ae or ACTOS\u00ae combination medicines, and PPAR Agonists (if any);\n9. Documents relating to samples of ACTOS\u00ae or ACTOS\u00ae combination medicines, and PPAR Agonists (if any), provided to Physicians or other Healthcare Professionals in the United States;\n10. Documents relating to marketing and promotion of ACTOS\u00ae or ACTOS\u00ae combination medicines and, and PPAR Agonists (if any) in the United States, including marketing/promotional materials, direct-to-consumer advertising, sales aids, visuals, sales scripts, sales guides, reminder pieces, sales training materials, IMS data, marketing plans, market analysis, and agreements with any person or firm hired to assist with marketing); and,\n11. Documents relating to advisory boards and key opinion leaders in the United States regarding ACTOS\u00ae or ACTOS\u00ae combination medicines, and PPAR Agonists (if any).\n\n<a id='adc01297-4e90-47e6-9ad1-07aec12efa1c'></a>\n\nFor purposes of identifying documents to be preserved, the terms \"relating to\" or \"regarding\" should be understood as broadly as possible and any doubts concerning particular documents should be resolved in favor of preservation. Appropriate preservation of documents in accordance with this Notice is of the highest priority for you and the Company.\n\n<a id='8791c92e-adff-4a7f-90f2-60d81527c4f7'></a>\n\nFor purposes of this Notice, the term \"documents\" should be understood to have the broadest possible meaning. It includes, but is not limited to, paper and electronically stored information:\n\n*   paper documents, includes without limitation, correspondence; faxes; memoranda; notes; desk files, working files, or other personal files; presentations; calendars; contracts or other agreements; financial statements and related materials; message slips; phone logs; reports; statements; manuals; advertisements and other marketing materials; and,\n*   electronically stored information, includes without limitation e-mails and attachments; electronic calendars, task lists, journals, and notes; user files such as Microsoft Word, Excel, or PowerPoint files or Adobe PDF files; video recordings; instant messages;\n\n<a id='94874466-db80-4a15-a892-176dbe51c841'></a>\n\n3\n\n<a id='db6f438b-07b8-4b86-8d25-269d01fea5ca'></a>\n\nConfidential - Subject to Protective Order\n\n<a id='172e8067-cc85-45c7-bb7c-994798fdf00c'></a>\n\nTAK-RIM30b6-00000827\n\n<a id='fbbf39f1-8d62-4fbc-b5ea-a02107e3b037'></a>\n\nSource: https://www.indupP5345-00015ts.ucsf.edu/docs/srjf0226",
            "chunks": [
                "d4ad3519-b0aa-4c1a-b05e-3e3b501c4f9f",
                "0e034c61-7e60-490d-a6f8-2aaffaf2b882",
                "adc01297-4e90-47e6-9ad1-07aec12efa1c",
                "8791c92e-adff-4a7f-90f2-60d81527c4f7",
                "94874466-db80-4a15-a892-176dbe51c841",
                "db6f438b-07b8-4b86-8d25-269d01fea5ca",
                "172e8067-cc85-45c7-bb7c-994798fdf00c",
                "fbbf39f1-8d62-4fbc-b5ea-a02107e3b037"
            ]
        }
    ],
    "grounding": {
        "d4ad3519-b0aa-4c1a-b05e-3e3b501c4f9f": {
            "box": {
                "left": 0.5904516577720642,
                "top": 0.06997115910053253,
                "right": 0.8831928372383118,
                "bottom": 0.1347237527370453
            },
            "page": 0,
            "type": "chunkText"
        },
        "0e034c61-7e60-490d-a6f8-2aaffaf2b882": {
            "box": {
                "left": 0.21835893392562866,
                "top": 0.14801667630672455,
                "right": 0.8813126683235168,
                "bottom": 0.5939598083496094
            },
            "page": 0,
            "type": "chunkText"
        },
        "adc01297-4e90-47e6-9ad1-07aec12efa1c": {
            "box": {
                "left": 0.1362217664718628,
                "top": 0.6015820503234863,
                "right": 0.8594271540641785,
                "bottom": 0.6735875606536865
            },
            "page": 0,
            "type": "chunkText"
        },
        "8791c92e-adff-4a7f-90f2-60d81527c4f7": {
            "box": {
                "left": 0.1366363763809204,
                "top": 0.6831427812576294,
                "right": 0.8793812990188599,
                "bottom": 0.8867956399917603
            },
            "page": 0,
            "type": "chunkText"
        },
        "94874466-db80-4a15-a892-176dbe51c841": {
            "box": {
                "left": 0.5064734816551208,
                "top": 0.900419294834137,
                "right": 0.5263796448707581,
                "bottom": 0.9172058701515198
            },
            "page": 0,
            "type": "chunkMarginalia"
        },
        "db6f438b-07b8-4b86-8d25-269d01fea5ca": {
            "box": {
                "left": 0.05828157067298889,
                "top": 0.9531840682029724,
                "right": 0.4446862041950226,
                "bottom": 0.9734686017036438
            },
            "page": 0,
            "type": "chunkMarginalia"
        },
        "172e8067-cc85-45c7-bb7c-994798fdf00c": {
            "box": {
                "left": 0.7563959956169128,
                "top": 0.9526851177215576,
                "right": 0.9735433459281921,
                "bottom": 0.9736084938049316
            },
            "page": 0,
            "type": "chunkMarginalia"
        },
        "fbbf39f1-8d62-4fbc-b5ea-a02107e3b037": {
            "box": {
                "left": 0.22159555554389954,
                "top": 0.9798094630241394,
                "right": 0.7799657583236694,
                "bottom": 0.9995104670524597
            },
            "page": 0,
            "type": "chunkMarginalia"
        }
    },
    "metadata": {
        "filename": "srjf0226_15.png",
        "org_id": null,
        "page_count": 1,
        "duration_ms": 5006,
        "credit_usage": 3.0,
        "job_id": "hbi6udzhv4kg35wpwo34eo2bb",
        "version": "dpt-2-20250919"
    }
}